<HTML>
<HEAD>
<TITLE>Form 8-K Dec 15, 2006</TITLE>
</HEAD>
<BODY>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>UNITED STATES<BR>SECURITIES AND
EXCHANGE COMMISSION</FONT><BR><FONT FACE="Times New Roman, Times, Serif" SIZE=2>WASHINGTON, D.C. 20549  </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM 8-K</FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT REPORT </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Minor Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Minor Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date of report (Date
of earliest event reported):&nbsp;&nbsp;December 15, 2006 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="4"><B>IDEXX LABORATORIES, INC.</B></FONT><BR><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
<I>(Exact name of registrant as specified in its charter)</I> </FONT> </P>


<BR>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=LEFT WIDTH=100%>
<TR VALIGN=Bottom>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Delaware</FONT></TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>000-19271</FONT></TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>01-0393723</FONT></TH></TR>
<TR VALIGN=Top>
     <TD WIDTH=30% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>(State or other jurisdiction<BR>of incorporation) </I> </FONT></TD>
     <TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
     <TD WIDTH=30% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>(Commission File Number)</I> </FONT></TD>
     <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
     <TD WIDTH=30% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>(IRS Employer<BR>Identification No.)</I> </FONT></TD>
     <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD></TR>
</TABLE>
<BR>
<BR>

<BR><BR>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 ALIGN=LEFT WIDTH=100%>
<TR VALIGN=Bottom>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>One IDEXX Drive, Westbrook, Maine</FONT></TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>04092</FONT></TH></TR>
<TR VALIGN=Top>
     <TD WIDTH=30% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Address of principal executive offices) </I> </FONT></TD>
     <TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
     <TD WIDTH=30% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>&nbsp;</I> </FONT></TD>
     <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
     <TD WIDTH=30% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>(ZIP Code)</I> </FONT></TD>
     <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD></TR>
</TABLE>
<BR>
<BR><BR>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>(207) 556-0300</B><BR><I>(Registrant&#146;s
telephone number, including area code)</I> </FONT> </P>
<BR>
<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Not Applicable</B><BR><I>(Former
name or former address, if changed since last report)</I> </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2): </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Large Hang Lv 1-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Written communications
purusant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Large Hang Lv 1-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Soliciting material
purusant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Large Hang Lv 1-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pre-commencement
communications purusant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Large Hang Lv 1-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pre-commencement
communications purusant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR>
</TABLE>
<BR>



<!-- MARKER PAGE="sheet: 2; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>



<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 1.01&nbsp;&nbsp;&nbsp;
Entry into a Material Definitive Agreement.</FONT></H1>


<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December 15, 2006, IDEXX Laboratories, Inc. and its subsidiary
IDEXX Sciences, Inc. (together, the &#147;Company&#148; or &#147;IDEXX&#148;) entered into a Purchase and Sale Agreement (the &#147;Purchase and
Sale Agreement&#148;) with Osmetech plc, Osmetech Technology Inc., Osmetech Inc. and Osmetech GmbH (collectively, &#147;Osmetech&#148;)
pursuant to which IDEXX will acquire Osmetech&#146;s Critical Care Division, which develops, manufactures and sells
electrolyte and blood gas analyzers and related consumable products (the &#147;Acquisition&#148;). The Acquisition is structured as
a purchase of assets for an aggregate purchase price of $44.9 million in cash and the assumption of certain liabilities
by IDEXX. The purchase price is subject to a post-closing adjustment based on the Critical Care Division&#146;s net asset
value as of the closing date of the Acquisition.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IDEXX
has made customary representations and warranties and covenants in the Purchase and Sale
Agreement, which also contains mutual indemnification obligations. The closing of the
Acquisition is contingent upon approval by the shareholders of Osmetech plc and is
subject to applicable foreign regulatory filing requirements and approvals and the
satisfaction of other customary closing conditions. The Acquisition is expected to close
on or around January 31, 2007. </FONT></P>



<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing description of the terms and conditions of the Purchase and Sale Agreement and
the Acquisition is not complete and is qualified in its entirety by reference to the
Purchase and Sale Agreement, which is filed as Exhibit 2.1 hereto and is incorporated
herein by reference. The Purchase and Sale Agreement has been included to provide
information regarding its terms. It is not intended to provide any other factual
information about IDEXX or Osmetech. Such information regarding IDEXX can be found in the
other public filings IDEXX makes with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;),
which are available without charge through the web site maintained by the SEC at
www.sec.gov. </FONT></P>



<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Apart
from the Acquisition, IDEXX currently purchases all of its VetStat<SUP>&#174;</SUP> electrolyte and blood
gas analyzers and consumables from Osmetech Inc., a wholly owned subsidiary of Osmetech
plc, and has also engaged Osmetech Inc. for the development and supply of next-generation
analyzer and consumables technologies. </FONT></P>



<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cautionary Note
Regarding Forward-Looking Statements. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements
in this document regarding the Acquisition, the expected effects, timing and completion
of the proposed transaction and any other statements about IDEXX&#146;s future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are
not statements of historical fact (including statements containing the words &#147;believes,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;expects,&#148; &#147;estimates&#148; and
similar expressions) should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including: the
ability to consummate the proposed transaction due to the failure to satisfy conditions
to the closing of the proposed transaction such as approval of the shareholders of
Osmetech plc, the ability to recognize the anticipated benefits of the transaction,
intense competition in IDEXX&#146;s industry, changes in government regulation, failure to
successfully integrate the assets, operations and employees of the acquired business and
other factors described in IDEXX&#146;s Annual Report on Form 10-K for the year ended December
31, 2005 and its most recent quarterly report filed with the SEC. In addition, any
forward-looking statements represent IDEXX&#146;s estimates only as of today and should not be
relied upon as representing IDEXX&#146;s estimates as of any subsequent date.  IDEXX disclaims
any intention or obligation to update any forward-looking statements as a result of
developments occurring after the date of this Current Report on Form 8-K. </FONT></P>



<!-- MARKER FORMAT-SHEET="Page Number Center" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2 </FONT></P>

<!-- MARKER PAGE="sheet: 2; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>






<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 9.01&nbsp;&nbsp;&nbsp;
Financial Statement and Exhibits.</FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(d)</FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibits</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>See the Exhibit Index
attached to this Report, which is incorporated herein by reference. </FONT></TD>
</TR>
</TABLE>
<BR>






<!-- MARKER FORMAT-SHEET="Page Number Center" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3 </FONT></P>

<!-- MARKER PAGE="sheet: 2; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>




<!-- MARKER FORMAT-SHEET="Head Sub 3 Left-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>SIGNATURES</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>




<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH></TH>
     <TH></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="50%"><FONT SIZE="2">Dated: December 21, 2006</FONT></TD>
     <TD WIDTH="50%"><FONT SIZE="2"><B>IDEXX LABORATORIES, INC.</B> </FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
     <TD><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT SIZE="2"></FONT></TD>
     <TD><FONT SIZE="2">By: /s/ Conan R. Deady</FONT><HR WIDTH=100% SIZE=1 COLOR=BLACK NOSHADE></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT SIZE="2"></FONT></TD>
     <TD><FONT SIZE="2">Conan R. Deady<BR>
Corporate Vice President, General Counsel and Secretary</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT SIZE="1"></FONT></TD>
     <TD><FONT SIZE="1"></FONT></TD></TR>
</TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Page Number Center" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4 </FONT></P>

<!-- MARKER PAGE="sheet: 2; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT INDEX</FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Exhibit No.</U>&nbsp;&nbsp;&nbsp;&nbsp;<U>Description of Exhibit</U> </FONT> </P>


<BR>
<!-- MARKER FORMAT-SHEET="Para Hang Level 1" FSL="Default" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.1 </FONT></TD>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Purchase and Sale Agreement among Osmetech plc, Osmetech
Inc., Osmetech Technology Inc. and Osmetech GmbH and IDEXX Sciences, Inc. and IDEXX Laboratories, Inc.
dated as of December 15, 2006<SUP>(1)</SUP>
</FONT></TD>
</TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Footnote Rule-TNR" FSL="Project" -->
<HR SIZE=1 NOSHADE WIDTH=15% ALIGN=LEFT>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 0-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><SUP>(1)</SUP>  </FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
schedules to the Purchase and Sale Agreement have been omitted from this filing pursuant
to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of any of such
schedules to the SEC upon request.</FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Number Center" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></P>

<!-- MARKER PAGE="sheet: 2; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "form8k_dec152006.htm", "description": "FORM 8-K DEC 15, 2006 ITEM 1.01", "secsgml_size_bytes": 17364}, {"type": "8-K", "sequence": "3", "filename": "form8k_12152006wexhibit.pdf", "description": "IDEXX FORM 8-K_12152006", "secsgml_size_bytes": 892561}]
{"company-data": {"conformed-name": "IDEXX LABORATORIES INC /DE", "cik": "0000874716", "assigned-sic": "2835", "irs-number": "010393723", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19271", "film-number": "061293026"}, "business-address": {"street1": "ONE IDEXX DRIVE", "city": "WESTBROOK", "state": "ME", "zip": "04092-2041", "phone": "2078560300"}, "mail-address": {"street1": "ONE IDEXX DRIVE", "city": "WESTBROOK", "state": "ME", "zip": "04092-2041"}, "former-company": {"former-conformed-name": "IDEXX CORP / DE", "date-changed": "19600201"}}
Form 8-K Dec 15, 2006
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of report (Date
of earliest event reported):  December 15, 2006
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-19271
01-0393723
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
One IDEXX Drive, Westbrook, Maine
04092
(Address of principal executive offices)
(ZIP Code)
(207) 556-0300
(Registrant's
telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2):
[  ]
Written communications
purusant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]
Soliciting material
purusant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]
Pre-commencement
communications purusant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]
Pre-commencement
communications purusant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01   
Entry into a Material Definitive Agreement.
On
December 15, 2006, IDEXX Laboratories, Inc. and its subsidiary
IDEXX Sciences, Inc. (together, the "Company" or "IDEXX") entered into a Purchase and Sale Agreement (the "Purchase and
Sale Agreement") with Osmetech plc, Osmetech Technology Inc., Osmetech Inc. and Osmetech GmbH (collectively, "Osmetech")
pursuant to which IDEXX will acquire Osmetech's Critical Care Division, which develops, manufactures and sells
electrolyte and blood gas analyzers and related consumable products (the "Acquisition"). The Acquisition is structured as
a purchase of assets for an aggregate purchase price of $44.9 million in cash and the assumption of certain liabilities
by IDEXX. The purchase price is subject to a post-closing adjustment based on the Critical Care Division's net asset
value as of the closing date of the Acquisition.
IDEXX
has made customary representations and warranties and covenants in the Purchase and Sale
Agreement, which also contains mutual indemnification obligations. The closing of the
Acquisition is contingent upon approval by the shareholders of Osmetech plc and is
subject to applicable foreign regulatory filing requirements and approvals and the
satisfaction of other customary closing conditions. The Acquisition is expected to close
on or around January 31, 2007.
The
foregoing description of the terms and conditions of the Purchase and Sale Agreement and
the Acquisition is not complete and is qualified in its entirety by reference to the
Purchase and Sale Agreement, which is filed as Exhibit 2.1 hereto and is incorporated
herein by reference. The Purchase and Sale Agreement has been included to provide
information regarding its terms. It is not intended to provide any other factual
information about IDEXX or Osmetech. Such information regarding IDEXX can be found in the
other public filings IDEXX makes with the U.S. Securities and Exchange Commission (the "SEC"),
which are available without charge through the web site maintained by the SEC at
www.sec.gov.
Apart
from the Acquisition, IDEXX currently purchases all of its VetStat
®
electrolyte and blood
gas analyzers and consumables from Osmetech Inc., a wholly owned subsidiary of Osmetech
plc, and has also engaged Osmetech Inc. for the development and supply of next-generation
analyzer and consumables technologies.
Cautionary Note
Regarding Forward-Looking Statements.
Statements
in this document regarding the Acquisition, the expected effects, timing and completion
of the proposed transaction and any other statements about IDEXX's future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are
not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," "estimates" and
similar expressions) should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including: the
ability to consummate the proposed transaction due to the failure to satisfy conditions
to the closing of the proposed transaction such as approval of the shareholders of
Osmetech plc, the ability to recognize the anticipated benefits of the transaction,
intense competition in IDEXX's industry, changes in government regulation, failure to
successfully integrate the assets, operations and employees of the acquired business and
other factors described in IDEXX's Annual Report on Form 10-K for the year ended December
31, 2005 and its most recent quarterly report filed with the SEC. In addition, any
forward-looking statements represent IDEXX's estimates only as of today and should not be
relied upon as representing IDEXX's estimates as of any subsequent date.  IDEXX disclaims
any intention or obligation to update any forward-looking statements as a result of
developments occurring after the date of this Current Report on Form 8-K.
2
Item 9.01   
Financial Statement and Exhibits.
(d)
Exhibits
See the Exhibit Index
attached to this Report, which is incorporated herein by reference.
3
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 21, 2006
IDEXX LABORATORIES, INC.
By: /s/ Conan R. Deady
Conan R. Deady
Corporate Vice President, General Counsel and Secretary
4
EXHIBIT INDEX
Exhibit No.
Description of Exhibit
2.1
Purchase and Sale Agreement among Osmetech plc, Osmetech
Inc., Osmetech Technology Inc. and Osmetech GmbH and IDEXX Sciences, Inc. and IDEXX Laboratories, Inc.
dated as of December 15, 2006
(1)
(1)
The
schedules to the Purchase and Sale Agreement have been omitted from this filing pursuant
to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of any of such
schedules to the SEC upon request.